Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial

Archives of Internal Medicine

Volumn 168, Issue 21, 2008, Pages 2326-2332

  Yu, Ying Ying ^a,b   Pinsky, Paul F ^a   Caporaso, Neil E ^a   Chatterjee, Nilanjan ^a   Baumgarten, Mona ^b   Langenberg, Patricia ^b   Furuno, Jon P ^b   Lan, Qing ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; COLORECTAL CANCER; FEMALE; HUMAN; LUNG CANCER; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SCAR FORMATION; THORAX RADIOGRAPHY;

EID: 56749173308     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.21.2326     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Brenner AV, Wang Z, Kleinerman RA, et al. Previous pulmonary disease and risk of lung cancer in Gansu Province, China. Int J Epidemiol. 2001;30(1):118-124.
3. Brownson RC, Alavanja MC. Previous lung disease and lung cancer risk among women (United States). Cancer Causes Control. 2000;11(9):853-858.
4. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol. 1995;141(11):1023-1032.
5. Hessel PA, Gamble JF, McDonald JC. Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence. Thorax. 2005;60(5):433-436.
6. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101(12):2534-2540.
7. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69-83.
8. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605-615.
9. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003;5(1):46-62.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
11. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192(7):1201- 1210.
12. Auerbach O, Garfinkel L, Parks VR. Scar cancer of the lung: increase over a 21 year period. Cancer. 1979;43(2):636-642.
13. Madri JA, Carter D. Scar cancers of the lung: origin and significance. Hum Pathol. 1984;15(7):625-631.
14. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6)(suppl):273S-309S.
15. Pinsky PF, Freedman M, Kvale PA, Oken MM, Caporaso N, Gohagan J. Abnormalities on chest radiograph reported in subjects in a cancer screening trial. Chest. 2006;130(3):688-693.
16. Oken MM, Marcus PM, Hu P, et al; PLCO Project Team. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2005;97(24):1832-1839.
17. Thurston SW, Liu G, Miller DP, Christiani DC. Modeling lung cancer risk in case-control studies using a new dose metric of smoking. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2296-2302.
18. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4):333-342.
19. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074-1078.
20. Quantin C, Abrahamowicz M, Moreau T, et al. Variation over time of the effects of prognostic factors in a population-based study of colon cancer: comparison of statistical models. Am J Epidemiol. 1999;150(11):1188-1200.
21. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
22. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther. 2003;2(3):238-246.
23. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocytegenerated oxidants in carcinogenesis. Blood. 1990;76(4):655-663.
24. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24(33):5216-5222.
25. Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67(13):6520-6527.